Ns Pharma, Inc.
Clinical trials sponsored by Ns Pharma, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for rare disease: can NS-229 help patients reduce steroids? Results expected Dec 2026 (estimated)
- New hope for duchenne: experimental drug targets genetic glitch Results expected Feb 2027 (estimated)
-
New pill could ease deadly lung pressure condition
Disease control Not yet recruitingThis Phase 2 trial tests an oral drug called NS-863 in 177 adults with pulmonary hypertension linked to interstitial lung disease (PH-ILD). Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goal is to see if the drug improves blood vessel r…
Phase 2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill could ease rare lung disease
Disease control Not yet recruitingThis Phase 2 trial tests an oral drug called NS-863 in 135 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe. Participants will receive either a low dose, high dose, or placebo for 24 weeks. The main goa…
Phase 2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC